Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;10(Suppl 2):S434-40.
doi: 10.4103/0973-1296.133300.

Phytochemical and anti-staphylococcal biofilm assessment of Dracaena draco L. Spp. draco resin

V Di Stefano  1 , R Pitonzo  2 , D Schillaci  1
Affiliations

Phytochemical and anti-staphylococcal biofilm assessment of Dracaena draco L. Spp. draco resin

V Di Stefano et al. Pharmacogn Mag. 2014 Apr.

Abstract

Background: Dracaena draco L. ssp. draco is known as the "dragon's blood tree" and it is endemic from the Canary Islands and Morocco.

Objective: Carry out phytochemical investigation of acetonic extracts of red resin obtained from the trunk of D. draco, to obtain to the isolation of the most abundant resin constituents, belonging to the class of flavonoids: flavans, along with homoisoflavans and homoisoflavanones.

Materials and methods: The structures of the isolated compounds were established by Nuclear Magnetic Resonance (NMR) and mass spectrometry data and comparison with literature data. The acetonic extract was evaluated for its anti-staphylococcal properties against two reference strains.

Results: The acetonic extracts resulted inactive at the maximum tested concentration of 1000 μg/ml against free living forms of tested staphylococci, but they showed a very interesting activity in the prevention of a biofilm formation at a concentration equal to 200 μg/ml against S. aureus ATCC 25923.

Keywords: Antibiofilm activity; Dracaena draco L.; dragon blood resin; flavan; homoisoflavan.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Dragon's blood resin from Dracaena draco
Scheme 1
Scheme 1
Structures of isolated compounds 1-16
Figure 2
Figure 2
Numbers (CFU/ml) of S. aureus ATCC 25923 in untreated biofilm and in the presence of Dracaena draco resin. Data reported as means ± SD
See this image and copyright information in PMC

References

    1. Pearson JJ, Prendergast HD. Daemonorops Dracaena and Other Dragon's Blood. Econ Bot. 2001;55:474–7.
    1. Gupta D, Bleakley B, Gupta RK. Dragon's blood: Botany, chemistry and therapeutic uses. J Ethnopharmacol. 2008;115:361–80. - PubMed
    1. Milburn M. Dragon's Blood in East and West Africa, Arabia and the Canary Islands. Africa. 1984;39:486–93.
    1. Ballabio R. Plantes médicinales endémiques de l’île de Madère. Phytothérapie. 2004;2:41–6.
    1. Silva BM, Santos RP, Mendes LS, Guedes de Pinho P, Valentão P, Andrade PB, et al. Dracaena draco L. fruit: Phytochemical and antioxidant activity assessment. Food Res Int. 2011;44:2182–9.

LinkOut - more resources